Evaluating targeted COVID-19 vaccination strategies with agent-based modeling.

We evaluate approaches to vaccine distribution using an agent-based model of human activity and COVID-19 transmission calibrated to detailed trends in cases, hospitalizations, deaths, seroprevalence, and vaccine breakthrough infections in Florida, USA. We compare the incremental effectiveness for four different distribution strategies at four different levels of vaccine supply, starting in late 2020 through early 2022. Our analysis indicates that the best strategy to reduce severe outcomes would be to actively target high disease-risk individuals. This was true in every scenario, although the advantage was greatest for the intermediate vaccine availability assumptions and relatively modest compared to a simple mass vaccination approach under high vaccine availability. Ring vaccination, while generally the most effective strategy for reducing infections, ultimately proved least effective at preventing deaths. We also consider using age group as a practical surrogate measure for actual disease-risk targeting; this approach also outperforms both simple mass distribution and ring vaccination. We find that quantitative effectiveness of a strategy depends on whether effectiveness is assessed after the alpha, delta, or omicron wave. However, these differences in absolute benefit for the strategies do not change the ranking of their performance at preventing severe outcomes across vaccine availability assumptions. Author Summary: We use our agent-based model of SARS-CoV-2 transmission to evaluate alternative vaccine distribution strategies over a range of vaccine supply scenarios. We find that strategies targeting transmission (e.g., ring vaccination) perform best in preventing infections, but targeting disease risk prevents more instances of severe outcomes. Specifically, strategies based on age, or age and comorbidities—which do not require contact tracing—resulted in the fewest hospitalizations in our model. These strategy rankings held true across all vaccine supply scenarios and were robust to the introduction of SARS-CoV-2 variants. While the quantitative results cannot be directly applied to other settings (as we used a synthetic population calibrated to the State of Florida), the rankings of strategies should be more generalizable. [ABSTRACT FROM AUTHOR]